Compare BIO-TECHNE Corp (TECH) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Teradyne, Inc. — how do they compare? BIO-TECHNE Corp trades at $72.07 (market cap $11.24B), while Teradyne, Inc. trades at $379.69 (market cap $57.08B). The key difference: Teradyne, Inc. is far larger — about 5.1× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals.
| TECH | TER | |
|---|---|---|
Market Cap | $11.24B | $57.08B |
Sector | Health | Technology |
52-Week High | $72.29 | $483.84 |
52-Week Low | $43.31 | $104.68 |
Enterprise Value | $11.32B | $56.83B |
Dividend Yield | 0.44% | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Teradyne (TER) trades at $379.31, down 1.45% today but maintains strong technical momentum with a bullish moving average signal. The company demonstrates robust fundamentals with record Q2 2026 earnings of $2.47 EPS beating estimates by 18%, driven by AI-led semiconductor test demand. Revenue grew to $3.19 billion in 2025 with impressive 25.77% net income margin and 36.66% ROE. Analyst consensus remains strongly bullish with 64.5% buy ratings and $481.63 price target representing 27% upside potential.
Teradyne presents compelling growth prospects fueled by AI-driven semiconductor testing demand and expanding robotics business. The stock trades at premium valuations (P/E 52.1, P/S 13.43) reflecting high growth expectations. Key risks include cyclical semiconductor industry exposure and execution challenges in scaling operations. Current technical positioning near pivot point ($384) suggests potential for breakout above resistance at $396 if earnings momentum continues through Q3 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
